Comparing to WHO2022, the ICC classified NUP98 rearrangements as “other rare recurring translocations” and two gene fusions (PRDM16::RPN1 and RUNX1::CBFA2T3) were classified as ‘other rare recurring translocations’, whereas the WHO2022 classified them as AML-Diff (Supplementary Table 2). This evidence concerns the gene PRDM16 and acute myeloid leukemia.